Background & Aims Little is known about substitutions that mediate resistance of hepatitis C
virus (HCV) to direct-acting antivirals (DAAs), due to the small number of patients with …

Introduction Real-world treatment of hepatitis C virus (HCV) infection is complicated by many
factors that are controlled for in the rigorous clinical trial setting. The aim of the present study …

Background & Aims Inhibitors of the hepatitis C virus (HCV) NS5A protein are a key
component of effective treatment regimens, but the genetic heterogeneity of HCV has limited …

Background Genotype 1b is the most common HCV genotype worldwide, accounting for the
largest proportion of infections in Europe, Russia, Latin America and Asia. Reducing …

Background The all-oral combination of daclatasvir 60mg QD, a first-in-class HCV NS5A
inhibitor with pan-genotypic activity in vitro, and asunaprevir 1 00mg BID, a selective NS3 …

In this study, we investigated the real‐world data of the first approved interferon‐free
regimen in Japan, daclatasvir and asunaprevir (DCV+ ASV), in chronic hepatitis C patients …

Resistance associated substitutions (RASs) can reduce the efficacy of direct-acting antiviral
agents (DAAs) targeting hepatitis C virus (HCV) and lead to treatment failure. Clinical data of …

Background & aims Resistance associated substitutions (RAS) can reduce the efficacy of
some direct-acting antiviral HCV regimens. Here, prevalence of RAS in genotype (GT) 1b, 2 …

Many direct‐acting antiviral regimens have reduced activity in people with hepatitis C virus
(HCV) genotype (GT) 3 infection and cirrhosis. The C‐ISLE study assessed the efficacy and …

Background Data on persistence of NS5A resistance-associated substitutions (RASs) may
have implications for resistance testing approaches and selection of initial and retreatment …